Radiopharmaceuticals used for in vivo imaging of inflammatory conditions can be conveniently classified into six categories according to the different phases in which the inflammatory process develops. The trigger BIOLOGICAL IMAGING Biodrugs 2002; 16 (4): 241-259 1173-8804/02/0004-0241/$25.00/0 © Adis International Limited. All rights reserved. of an inflammatory process is a pathogenic insult (phase I) that causes activation of endothelial cells (phase II); there is then an increase of vascular permeability followed by tissue oedema (phase III). Phase IV is characterised by infiltration of polymorphonuclear cells, and a self-limiting regulatory process called apoptosis is observed (phase V). If the inflammatory process persists, late chronic inflammation takes place (phase VI). In some pathological conditions, such as organ-specific autoimmune diseases, chronic inflammation is present early in the disease. The aim of nuclear medicine in the field of inflammation/infection is to develop noninvasive tools for the in vivo detection of specific cells and tissues. This would allow early diagnosis of initial pathophysiological changes that are undetectable by clinical examination or by other diagnostic tools, and could also be used to evaluate the state of activity of the disease during therapy. These potential applications are of great interest in clinical practice. In this review, we describe the various approaches that have been developed in the last 25 years of experience. Recent advances in the diagnosis of inflammatory processes have led to the development of specific radiopharmaceuticals that are intended to allow specific stage-related diagnosis.

Biological imaging for the diagnosis of inflammatory conditions / Signore, Alberto; Annovazzi, A.; Corsetti, F.; Capriotti, Gabriela; Chianelli, M.; De Winter, F.; Scopinaro, Francesco. - In: BIODRUGS. - ISSN 1173-8804. - STAMPA. - 16:(2002), pp. 241-259.

Biological imaging for the diagnosis of inflammatory conditions

SIGNORE, Alberto;CAPRIOTTI, Gabriela;SCOPINARO, Francesco
2002

Abstract

Radiopharmaceuticals used for in vivo imaging of inflammatory conditions can be conveniently classified into six categories according to the different phases in which the inflammatory process develops. The trigger BIOLOGICAL IMAGING Biodrugs 2002; 16 (4): 241-259 1173-8804/02/0004-0241/$25.00/0 © Adis International Limited. All rights reserved. of an inflammatory process is a pathogenic insult (phase I) that causes activation of endothelial cells (phase II); there is then an increase of vascular permeability followed by tissue oedema (phase III). Phase IV is characterised by infiltration of polymorphonuclear cells, and a self-limiting regulatory process called apoptosis is observed (phase V). If the inflammatory process persists, late chronic inflammation takes place (phase VI). In some pathological conditions, such as organ-specific autoimmune diseases, chronic inflammation is present early in the disease. The aim of nuclear medicine in the field of inflammation/infection is to develop noninvasive tools for the in vivo detection of specific cells and tissues. This would allow early diagnosis of initial pathophysiological changes that are undetectable by clinical examination or by other diagnostic tools, and could also be used to evaluate the state of activity of the disease during therapy. These potential applications are of great interest in clinical practice. In this review, we describe the various approaches that have been developed in the last 25 years of experience. Recent advances in the diagnosis of inflammatory processes have led to the development of specific radiopharmaceuticals that are intended to allow specific stage-related diagnosis.
2002
01 Pubblicazione su rivista::01a Articolo in rivista
Biological imaging for the diagnosis of inflammatory conditions / Signore, Alberto; Annovazzi, A.; Corsetti, F.; Capriotti, Gabriela; Chianelli, M.; De Winter, F.; Scopinaro, Francesco. - In: BIODRUGS. - ISSN 1173-8804. - STAMPA. - 16:(2002), pp. 241-259.
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/501631
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 16
social impact